Tags

Type your tag names separated by a space and hit enter

Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma.
Am J Respir Crit Care Med. 1994 Jul; 150(1):17-22.AJ

Abstract

The effect of prolonged inhaled corticosteroid treatment on bronchial immunopathology was assessed in 25 nonsmoking mildly asthmatic subjects previously receiving intermittent inhaled beta 2-agonist alone. Inhaled beclomethasone dipropionate (BDP), 500 micrograms twice per day or placebo was administered for 4 mo in a double-blind parallel group study. Histamine bronchial provocation, fiberoptic bronchoscopic biopsy, and bronchoalveolar lavage (BAL) were performed before and after treatment. There was no difference in bronchial responsiveness or lung function between groups. In patients treated with BDP compared with placebo, there was a significant reduction in toluidine blue-staining mast cells (p = 0.028) and total (p = 0.005) and activated eosinophils (p = 0.05) in biopsies but no difference in eosinophils or eosinophil cationic protein in BAL. Granulocyte-macrophage colony-stimulating factor expression was significantly reduced in the bronchial epithelium, and the thickness of Type III collagen deposition in the bronchial lamina reticularis reduced from 29.7 +/- 4.4 to 19.8 +/- 3.4 microns (mean +/- 95% confidence interval) (p = 0.04). No change in helper or activated helper T cells occurred. Prolonged BDP treatment reduces inflammatory infiltration, proinflammatory cytokine expression, and subepithelial collagen deposition, a recognized abnormality in asthma.

Authors+Show Affiliations

Department of Respiratory Medicine and Allergy, St. Bartholomew's Hospital, London, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8025745

Citation

Trigg, C J., et al. "Placebo-controlled Immunopathologic Study of Four Months of Inhaled Corticosteroids in Asthma." American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 1, 1994, pp. 17-22.
Trigg CJ, Manolitsas ND, Wang J, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med. 1994;150(1):17-22.
Trigg, C. J., Manolitsas, N. D., Wang, J., Calderón, M. A., McAulay, A., Jordan, S. E., Herdman, M. J., Jhalli, N., Duddle, J. M., & Hamilton, S. A. (1994). Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. American Journal of Respiratory and Critical Care Medicine, 150(1), 17-22.
Trigg CJ, et al. Placebo-controlled Immunopathologic Study of Four Months of Inhaled Corticosteroids in Asthma. Am J Respir Crit Care Med. 1994;150(1):17-22. PubMed PMID: 8025745.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. A1 - Trigg,C J, AU - Manolitsas,N D, AU - Wang,J, AU - Calderón,M A, AU - McAulay,A, AU - Jordan,S E, AU - Herdman,M J, AU - Jhalli,N, AU - Duddle,J M, AU - Hamilton,S A, PY - 1994/7/1/pubmed PY - 1994/7/1/medline PY - 1994/7/1/entrez SP - 17 EP - 22 JF - American journal of respiratory and critical care medicine JO - Am J Respir Crit Care Med VL - 150 IS - 1 N2 - The effect of prolonged inhaled corticosteroid treatment on bronchial immunopathology was assessed in 25 nonsmoking mildly asthmatic subjects previously receiving intermittent inhaled beta 2-agonist alone. Inhaled beclomethasone dipropionate (BDP), 500 micrograms twice per day or placebo was administered for 4 mo in a double-blind parallel group study. Histamine bronchial provocation, fiberoptic bronchoscopic biopsy, and bronchoalveolar lavage (BAL) were performed before and after treatment. There was no difference in bronchial responsiveness or lung function between groups. In patients treated with BDP compared with placebo, there was a significant reduction in toluidine blue-staining mast cells (p = 0.028) and total (p = 0.005) and activated eosinophils (p = 0.05) in biopsies but no difference in eosinophils or eosinophil cationic protein in BAL. Granulocyte-macrophage colony-stimulating factor expression was significantly reduced in the bronchial epithelium, and the thickness of Type III collagen deposition in the bronchial lamina reticularis reduced from 29.7 +/- 4.4 to 19.8 +/- 3.4 microns (mean +/- 95% confidence interval) (p = 0.04). No change in helper or activated helper T cells occurred. Prolonged BDP treatment reduces inflammatory infiltration, proinflammatory cytokine expression, and subepithelial collagen deposition, a recognized abnormality in asthma. SN - 1073-449X UR - https://www.unboundmedicine.com/medline/citation/8025745/Placebo_controlled_immunopathologic_study_of_four_months_of_inhaled_corticosteroids_in_asthma_ DB - PRIME DP - Unbound Medicine ER -